Background. Influenza vaccine effectiveness is not optimal in solid organ transplant recipients (SOTR). We hypothesized that a booster dose might increase it.
Influenza is an acute respiratory infection with a spectrum of disease that ranges from a self-limited febrile illness to a highly severe disease. Solid organ transplant recipients (SOTR) are at higher risk for acquiring influenza infection [1] with worse morbidity outcomes [2] . Annual inactivated trivalent influenza vaccination (TIV) is internationally recommended and it is the most effective strategy for reducing the incidence and complications of influenza disease in SOTR [3] [4] [5] . However, the immunological response to the influenza vaccine is heterogeneous in this population, with rates of seroprotection that range from 15% to 90% [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , generally lower than those of healthy individuals [8] . This response is influenced by several factors including type of immunosuppression, time from transplantation, and type of graft. Different strategies have been assessed to optimize the efficacy and immunogenicity of influenza vaccination in SOTR, including subcutaneous administration of the vaccine [21] , high-dose intradermal vaccination [21] , or the addition of an adjuvant in the composition of the vaccine [19] . However, no clear advantages with respect to conventional TIV administration have been shown.
We have previously reported that baseline detectable antibody titers against influenza strains were associated with higher postvaccination responses in SOTR [22] . Unfortunately, only around 30% of SOTR maintain titers 1 year after seasonal vaccination [22] . Therefore, annual vaccination has a limited booster effect with respect to maintaining baseline titers. However, the booster strategy might be feasible if administered within weeks after the standard dose, and may result in the production of a more robust immune response in SOTR, thus effectively improving the response in the current influenza seasons. To date, no published randomized controlled trial has explored this strategy in SOTR.
The TRANSGRIPE 1-2 study hypothesized that the efficacy and immunogenicity of the seasonal inactivated TIV can be increased in SOTR who receive a second dose 5 weeks after the standard influenza vaccine [23] .
METHODS

Study Design
The TRANSGRIPE 1-2 study is a publicly funded, phase 3, parallel-group, randomized controlled, open-label, multicenter clinical trial designed to assess the safety and efficacy of a booster dose of the influenza vaccine in SOTR. The trial design has been previously published [23] .
Study Participants and Clinical Settings
The study included SOTR (liver, kidney, heart or lung) ≥16 years of age, who signed informed consent form and were recruited at least 30 days after transplantation. Exclusion criteria were acute graft rejection within 15 days before selection, documented allergy and/or previous intolerance and/or contraindications to active compounds or excipients or any traces and/or residues in the vaccine, previous medical record of any severe adverse reaction to influenza vaccine, and confirmed pregnancy [23] . Patients were enrolled in 12 Spanish hospitals from 1 October 2012 through 31 December 2012.
Randomization and Vaccination
Randomization was generated in blocks with a 1:1 ratio, stratified by study sites, posttransplant period (1-6 months, >6-12 months, and > 12 months), and type of recipient (liver, kidney, lung, heart), to avoid selection bias due to immunosuppression schedules. The randomization process has been previously published [23] . Patients were randomly assigned to receive the standard intramuscular single-dose vaccination (control group) or to the experimental group with a second dose of the same influenza vaccine 5 weeks apart (booster group).
A nonadjuvanted TIV (Mutagrip, Sanofi-Pasteur MSD) was administrated by intramuscular injection (0.5 mL, containing the 3 influenza strains recommended by the World Health Organization for the Northern Hemisphere and European Union in the 2012-2013 season): influenza A/ California/7/2009(H1N1)pdm09-like virus, influenza A/ Victoria/361/2011(H3N2)-like virus, and influenza B/ Wisconsin/1/2010-like virus [23] .
Follow-up Protocol and Safety Assessment
The duration of the trial was 14 months: 2 months for patient enrollment and 12 months for patient follow-up. Blood samples were analyzed at baseline, at short term (10 weeks after first vaccine dose), and at long term (a year after vaccination) timepoints. Patients were prompted to notify the clinician of the onset or continuation of symptoms related to influenza infection occurring during the follow-up period or by email or telephone if symptoms arose during the period between visits. In cases of symptoms, a nasopharyngeal swab was taken for the detection of influenza infection using reverse-transcription polymerase chain reaction assays. All adverse events were recorded at each visit during follow-up and classified according to MedDRA [24] . Graft rejection was confirmed using biopsies or those clinically suspected that were favorably treated. As biopsies were not routinely performed, asymptomatic rejection was not evaluated in this study. Patients were withdrawn from the study if they did not attend 2 consecutive visits or if a change in treatment was needed (for details, see Supplementary Materials).
Laboratory Assays
Neutralizing antibody responses were evaluated using microneutralization assays as previously described [22, 25] (Supplementary Materials).
Outcome Measures
Immunological response (vaccine effectiveness) was based on the following international EMEA/CPMP 1997 criteria for use in influenza trials [26] : (1) seroprotection rate (the proportion of vaccinated individuals achieving titers ≥1:40) >70% (age 18-60 years) or >60% (age >60 years); (2) seroconversion rate (negative prevaccination serum that reached postvaccination titers >1:40 or 4-fold increase in antibody titers) >40% (age 18-60 years) or >30% (age >60 years); and (3) geometric mean titer (GMT), defined as the mean antibody titer after vaccination.
Seroconversion was the primary endpoint variable of the study. Secondary end-points included immunological response such as seroprotection rate and postvaccine GMT at short-term and long-term in the 2 treatment arms. The number needed to treat (NNT), defined as the number of SOTR that needed to be vaccinated with a booster dose to prevent the lack of seroprotection/seroconversion response in 1 patient, compared to the standard vaccination was also analyzed.
Clinical Efficacy
Vaccination clinical efficacy was analyzed considering all microbiologically confirmed cases of influenza disease during follow-up.
Sample Size Calculation
The sample size was estimated for the primary outcome of postvaccine seroconversion in a previous cohort of SOTR [22, 23] . Assuming α = .05, an 80% statistical power to observe differences using bilateral contrast hypothesis, an increase in the primary endpoint of 10% and a 10% estimate dropout rate per arm, the total number of patients needed was 514 (257 participants per treatment arm). Sample size was calculated using the online Simple Interactive Statistical Analysis calculator.
Statistical Analysis
Analyses were conducted by intention-to-treat (ITT), modified intention-to-treat (mITT), and per-protocol (PP) methods. The ITT analysis includes all patients who agreed to participate in the study, signed an informed consent form, and were randomized to the experimental group or the control group, and received the first vaccination dose. One study site (No. 11, n = 75) was excluded from the mITT population due to an excess of patients' withdrawal (because they were co-participating in another clinical trial). Because patients were randomized 1:1 by study site, the exclusion of a center did not violate the randomization. Per-protocol analysis included patients who were randomized, excluding those who registered protocol violations (patients who did not received vaccine per randomization) or who did not have pre-or postvaccination samples, allocated to the booster group and to the control group ( Figure 1 ).
Safety analyses were performed on the safety population (equivalent to the ITT population).
The statistical analyses have been previously described [23] . A bivariate analysis using a χ 2 test was used for categorical variables. For quantitative variables, Student t tests based on their distribution were used. The relative risks were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). Multivariate models were used to adjust for possible confounding variables including those variables associated in the bivariate analysis and those considered clinically relevant. All calculations were performed using SPSS version 18.0 software (SPSS, Chicago, Illinois).
RESULTS
Study Population
Baseline characteristics of patients of the mITT population were similar between treatment groups, except for tacrolimus treatment that was more frequent in the control group (80.3% vs 71.1%; P = .027; Table 1 ).
Short-term Immunogenicity
The results of the analysis of the mITT cohort show that at 10 weeks after the first vaccine dose, 2 doses of influenza vaccine were only associated with a higher seroconversion rate to influenza A(H1N1)pdm in the bivariate analyses (46.7% vs 32.7%; OR, 1.81 [95% CI, 1.01-3.24]; P = .046), but not when controlled for possible confounding factors such as age, sex, time since transplant, type of organ, use of high dose of mycophenolate mofetil (>2 g daily), tacrolimus, prior influenza vaccination, treatment with statins, and baseline detectable titers (Tables 2 and 3 ). However, in the PP analysis, having a booster dose of TIV was independently associated with short-term seroconversion for all the influenza strains (Supplementary Table 2 ). The NNT to achieve seroconversion was 7 patients for all influenza types. The booster dose group achieved an effective seroconversion rate (>40%) for all influenza strains, while the control group achieved this endpoint only for influenza B (Supplementary  Table 1 ) [26] .
The rate of seroprotection in the mITT analysis was higher in the booster compared with the control group, for the 3 types of influenza virus studied: 54% vs 43 Table 2) , and was independently associated with higher seroprotection rates (Table 3 ). The NNT to achieve 1 patient seroprotected was ≤10 for the 3 influenza strains ( Table 2) .
The rates of seroprotection to at least 1, 2, or 3 influenza strains according to the arm of treatment were also assessed. After adjusting for possible confounding factors, 2 doses of TIV were independently associated with a higher seroprotection rate to at least 1 strain: 86.3% vs 75.6% (OR, 1.92 [95% CI, 1.14-3.18]; P = .014) and to at least 2 influenza strains: 70.6% vs 53.5% (OR, 2.26 [95% CI, 1.49-3.45]; P < .001; Table 4 ). In the PP analysis, 2 doses of TIV were independently associated to seroprotection for all the influenza types (Supplementary  Tables 1-3) .
Short-term postvaccination GMTs in the mITT analysis were significantly higher in the booster group than in the control group (in the bivariate analysis but not in the multivariate analyses; Tables 2 and 3) Tables 1 and 2 ).
When patients seroprotected at baseline were excluded, no differences were observed regarding short-term seroprotection and postvaccine GMT (Supplementary Tables 10-12) .
Immunological response was not independently associated with time from transplantation (1-6 months, > 6-12 months, and >12 months) (Tables 3 and 4 
Long-term Immunogenicity (1 Year After Vaccination)
No differences between treatment groups regarding rates of seroconversion, seroprotection, and GMT were observed 1 year after vaccination. Moreover, a decrease in the GMT was observed at long term in both groups, with a 1.9-and 2.6-fold reduction for A(H1N1)pdm and 1.4-and 2.3-fold reduction for influenza B, in the control and booster groups, respectively (Table 2) .
Sensitivity analyses comparing these 3 types of analysis (ITT, mITT, and PP) and their outcome in immunogenicity are shown in Supplementary Figure 1 
Clinical Cases of Influenza Infection
Five patients (1%) were diagnosed with influenza infection at 3-6 months after vaccination (0.8% control group vs 1.2% booster group, P > .05). Three of these patients were seroprotected 10 weeks after vaccination. All patients experienced mild symptoms and favorable outcomes, with no influenza related-complications (Supplementary Table 7) .
Vaccination Safety
During follow-up, a total of 238 adverse events were recorded: 376 mild, 154 moderate, and 43 severe without differences between groups (Supplementary Table 8 ). The incidence of adverse events was not statistically different between treatment groups (P > .05).
There were 5 cases of graft rejection (P = .669 between groups); all of them were vaccinated after at least 6 months from transplantation (Supplementary Table 9 ).
DISCUSSION
This is the first randomized controlled trial comparing the use of a booster dose of TIV with the standard single dose, in adult SOTR. Our results demonstrate that a booster dose of the influenza vaccine, 5 weeks after initial immunization, is safe and achieved a better short-term immunological response for the 3 influenza strains included in the TIV-A(H1N1)pdm, A(H3N2), and influenza B-compared with the standard 1-dose vaccination.
Influenza vaccination in SOTR is the most proven useful approach against influenza infection and its related complications [3] . However, vaccination effectiveness is classically constrained by the heterogeneous and low immunological response [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Several strategies had been previously evaluated to improve the efficacy of vaccination in SOTR. Adjuvanted vaccines did not improved immunological response in SOTR during the pandemic influenza in 2009 [1, 9, 14, 16, [27] [28] [29] [30] [31] [32] . Higher doses of influenza antigens by intramuscular administration [33] have also been tested only in children SOTR with no proven benefits. Additionally, intradermal administration of the vaccine [21, 34, 35] did not demonstrate improved effectiveness, except in certain subgroups of patients [21, 35] .
On the other hand, baseline detectable influenza antibody titers have been correlated with higher postvaccination titers in SOTR [22] . However, influenza antibody titers are frequently undetectable at long term, with only 30% of SOTR who showed an immunological response after 5 weeks remaining seroprotected 1 year after vaccination [22] . Due to this progressive decline in antibody titers after vaccination, annual vaccination is not a valid strategy to provide baseline antibody titers prior to vaccination.
Another possibility is the administration of a booster dose of the influenza vaccine; however, this approach has shown discrepancies in previous reports. While some studies have reported a better effectiveness with a second dose of influenza vaccine-TIV and/or adjuvanted [12, 30, 36, 37 ]-other authors have reported no improvement of the response to vaccination in SOTR receiving 2 doses of the influenza vaccine, for both seasonal [6, 13, 38] and adjuvanted pandemic vaccines [9, 14] . The heterogeneity of the studies precludes firm conclusions about the booster strategy in the SOTR population. The optimal timing and frequency of booster dosing also remains unclear. To our knowledge, to date no randomized controlled trial evaluating the benefit of the administration of a booster dose of the influenza vaccine in SOTR has been published.
In this study, the use of a booster dose of TIV was associated with higher short-term seroconversion rate in the PP but not in the mITT analysis and higher seroprotection to at least 1 or 2 influenza antigens, when controlled for other possible confounding variables in the mITT analysis. Indeed, only the use of 2 doses of influenza vaccine achieved the standards established internationally for seroconversion and seroprotection (to at least 1 and 2 antigens) [26] . Moreover, the NNT estimated in this clinical trial to have a beneficial impact in 1 patient with a booster strategy was low, <10 patients, for the 3 influenza strains, with an effective increase between 10% and 16% (absolute risk reduction). Considering these results together with the safety of the administration of 2 doses of influenza vaccination in SOTR, the booster strategy should be considered an efficient measure. Although having a booster dose was not independently associated with the primary end-point seroconversion rate in the mITT analysis, the secondary endpoint seroprotection did. In fact, postvaccination seroprotection offers overall information regarding patients who were really protected from influenza (antibody titers ≥1:40), which is the main goal of influenza vaccination. In addition, the sample size estimate was achieved for both immunological endpoints, seroconversion, and seroprotection (Supplementary Materials).
Clinical efficacy of vaccination was very high, nearly 100%, in both treatment arms, which might have prevented the detection of differences between them. Besides that, all cases of influenza infection were mild with favorable outcome. Previous results showed that seasonal vaccination does not preclude the consideration of influenza infection in SOTR during influenza epidemic but has been associated with a lower incidence of related complications such as pneumonia [39] . A possible explanation of vaccination failure may be related with progressive antibody loss during follow-up, lacking seroprotection at the time of infection. Furthermore, low titers at short term in these patients, <1:120 and <1:160, although seroprotective by definition, only would have reduced infection by 50% [40] .
Given the decreased long-term antibody titers after influenza vaccination, regardless of the treatment arm, the annual vaccination campaign needs to be reinforced in SOTR. A reduction between the time of the administration of the vaccine with respect to the probable onset of the influenza epidemic might improve vaccine efficacy.
Some limitations of the study need to be mentioned. First, because no routine biopsies were performed, some episodes of asymptomatic rejection might have not been diagnosed. However, during patient follow-up, all complications, including clinical evidence of rejection, were recorded. Second, the number of lung transplant patients was small in the mITT population, so results may not be applicable to lung recipients. However, the PP analysis included a considerable number of lung recipients (n = 72), and the booster dose was effective. Third, most patients had received the influenza vaccine the previous year, as recommended [4, 5] , which probably led to a high baseline seroprotection rate. It is possible that these results might not be applied to less compliant patients, in terms of yearly influenza vaccination in SOTR. Finally, it is possible that some cases of influenza infection, especially those asymptomatic or with mild symptoms, might be misdiagnosed; however, given Against Influenza A(H1N1)pdm, Influenza A(H3N2), and Abbreviations: ARR, absolute risk reduction; CI, confidence interval; GMT, geometric mean ratio; NNT, number needed to treat with 2 doses to prevent the lack of seroprotection/seroconversion response in 1 patient; OR, odds ratio. *P < .05; **P < .01. All other comparisons by arm P > .05. the randomized design of the study, this would have affected both study arms. In summary, this is the first randomized controlled trial that reports a vaccination strategy that improves immunological effectiveness of influenza vaccination in SOTR. Two doses of influenza vaccine were as safe as a single dose, when beginning administration beyond the first month after transplantation. The safety and relevance of these results, with an NNT for seroconversion and seroprotection below 10 patients, generate good-quality evidence to support the seasonal use of 2 doses of the influenza vaccine in SOTR beyond the first month after transplantation.
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Notes
*P < .05; **P < .01. All other comparisons by arm P > .05.
